BioPharma Dive

Welcome to BioPharma Dive! We aim to give busy professionals a quick overview of the BioPharma sector in just 60 seconds.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#233922

United States

#84489

Health/Biotechnology and Pharmaceuticals

#63

Traffic sources

Monthly visitors

Articles

Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO

3 days ago | biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo

New drugs, however heralded, take time to embed into clinical care. Enhertu, the powerful antibody-drug conjugate from Daiichi Sankyo and AstraZeneca, was first approved in the U.S. in 2019, before the world had even heard of a novel coronavirus.
J&J data support earlier use of combo pill in prostate cancer

4 days ago | biopharmadive.com | Jonathan Gardner

CHICAGO — A Johnson & Johnson drug currently used for advanced prostate cancer can help keep the disease from progressing in men who are at earlier stages and have certain genetic mutations, according to newly unveiled data from a Phase 3 clinical trial. Results from this trial, named Amplitude, were released Tuesday at the American Society of Clinical Oncology’s meeting in Chicago.
Kymera, with new data, takes early step toward a Dupixent-like pill

5 days ago | biopharmadive.com | Gwendolyn Wu

Dive Brief:An experimental protein-degrading drug from Kymera Therapeutics appeared safe and able to affect its intended target in an early-stage clinical trial, leading shares in the biotechnology company to climb by nearly 50%. Data from a Phase 1 study in healthy volunteers showed that all dose levels of Kymera’s therapy, KT-621, either completely or nearly completely degraded a key protein in the blood and skin that’s linked to inflammation.
Bispecific competition, debating oral SERDs and a bold GLP-1 prediction

5 days ago | biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo

CHICAGO — The American Society of Clinical Oncology’s annual meeting is a forum for data. On Monday, it was also the backdrop to oncology’s latest deal, when Bristol Myers Squibb and BioNTech announced a multibillion-dollar alliance around a newly in-vogue drug. BioNTech’s drug is a bispecific antibody that simultaneously targets the proteins PD-L1 and VEGF.
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising

6 days ago | biopharmadive.com | Ned Pagliarulo |Jonathan Gardner

Funding cancer research isn't usually a political flashpoint. But as the Trump administration signals its desire to drastically cut the budget of the National Cancer Institute, the American Society of Clinical Oncology is finding itself forced to defend what is usually a bipartisan policy. "If implemented, these cuts would be devastating to the pace and progress of cancer research in America," ASCO CEO Clifford Hudis said in a Friday statement.
AstraZeneca drug could help keep a common breast cancer at bay

6 days ago | biopharmadive.com | Ned Pagliarulo

Too often, cancer has a way of evading treatment. Tumors that were held in check begin to spread anew, forcing doctors to try different drugs in a desperate race to keep malignant cells from multiplying. For a common type of breast cancer, this usually happens because of changes in a gene called ESR1. Mutations there can drive cancer growth even as physicians’ first choice of therapy chokes off the resources that tumors had relied on to survive. Afterwards, the prognosis for patients gets worse.
At ASCO, Enhertu cements growing role in stomach cancer care

1 week ago | biopharmadive.com | Jonathan Gardner

AstraZeneca and Daiichi Sankyo’s targeted cancer medicine Enhertu helped participants in a late-stage clinical trial with a type of advanced gastric cancer live longer than those who received a commonly prescribed, two-drug regimen involving chemotherapy. The finding, detailed Saturday at the American Society of Clinical Oncology’s annual meeting, gives physicians a clearer choice for when patients’ disease progresses after initial treatment.
Mixed COPD results for Regeneron, Sanofi drug cloud approval chances

1 week ago | biopharmadive.com | Ned Pagliarulo

A closely watched biologic drug for chronic obstructive pulmonary disease failed one of two large, late-stage studies, sending shares in its developers, Regeneron Pharmaceuticals and Sanofi, sliding downward Friday. While the drug, called itepekimab, met its goal in the other trial, the split findings cloud the prospects for Regeneron and Sanofi to seek approval on the basis of the current data.
HHS terminates Moderna contract to develop bird flu vaccine

1 week ago | biopharmadive.com | Delilah Alvarado

The U.S. The Department of Health and Human Services has canceled a contract with Moderna to develop messenger RNA vaccines against influenza strains seen as potential pandemic risks, leaving the future of the underlying research uncertain. Moderna revealed in a statement Wednesday that the HHS had terminated the contract, which could have handed the company more than $700 million in total funding.
Merck, Daiichi pull approval application for ADC in lung cancer

1 week ago | biopharmadive.com | Ben Fidler

Merck & Co. and Daiichi Sankyo have withdrawn an approval application in the U.S. for a lung cancer drug at the center of a multibillion-dollar alliance the companies formed two years ago. In a short statement Thursday, the companies said they’ve pulled a Food and Drug Administration submission for an experimental therapy known as patritumab deruxtecan.